SCHEMBL20710424

SCHEMBL20710424

CN(CCOc1ccccc1)c1cc(N2CCOCC2)nc(-c2cccnc2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 8/20 0.54
▸ PDE10A Q9Y233 1/20 0.50
▸ PIK3CA P42336 1/20 0.48
▸ PIK3CB P42338 1/20 0.48
▸ PIK3CG P48736 1/20 0.48
▸ ROS1 P08922 3/20 0.47
▸ HTT P42858 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ MAPT P10636 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ FFAR1 O14842 1/20 0.45
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20710493 0.88 GBA1 (0.52) GBA1ROS1ALDH1A1CYP3A4CYP2C9
SCHEMBL20710429 0.86 GBA1 (0.51) GBA1ALDH1A1TSHRHSD17B10CYP1A2
SCHEMBL20710490 0.85 GBA1 (0.54) GBA1ROS1ALDH1A1
SCHEMBL20710491 0.84 GBA1 (0.51) GBA1ROS1ALDH1A1
SCHEMBL20710489 0.84 GBA1 (0.51) GBA1ROS1ALDH1A1
SCHEMBL20710471 0.81 GBA1 (0.65) GBA1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL20710506 0.81 GBA1 (0.65) GBA1ALDH1A1SMN1; SMN2MAPK1KMT2A
SCHEMBL20710518 0.80 GBA1 (0.62) GBA1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL13309782 0.73 CYP3A4 (0.64) GBA1PDE10APIK3CAPIK3CBPIK3CG
SCHEMBL20710421 0.72 GBA1 (0.66) GBA1PDE10ASMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200283444-A1 SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF NORTHWESTERN UNIVERSITY 2020-09-10 — — US disclosed
WO-2019027765-A1 SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THERE NORTHWESTERN UNIVERSITY (US) 2019-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200283444-A1 SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF GBA3, GBA1, GBA2 GBA1 2/4885PDE10A 1195/4885PIK3CA 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback